Clinical Research Directory
Browse clinical research sites, groups, and studies.
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
Sponsor: Montefiore Medical Center
Summary
Investigators will test a novel protocol for starting BUP (buprenorphine-naloxone) treatment. The BUP microdose induction protocol has participants start very low doses of BUP without stopping other opioids that they are taking. The treatment as usual (TAU) has participants stop other opioids and experience opioid withdrawal before starting BUP. Investigators propose to test BUP microdose inductions vs. TAU in a randomized controlled trial.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
23
Start Date
2022-09-29
Completion Date
2025-04-09
Last Updated
2026-05-08
Healthy Volunteers
No
Interventions
BUP microdose induction
Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists). Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours
TAU
2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
Linkage to outpatient BUP treatment
Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
Locations (1)
Montefiore Medical Center
The Bronx, New York, United States